KABIKINASE - PWS 250000 UNIT/VIAL 250000 UNIT
STREPTOKINASE : 250000 UNIT · DIN 02126125 · PHARMACIA & UPJOHN INC
Health Canada status: CANCELLED POST MARKET
What is KABIKINASE - PWS 250000 UNIT/VIAL?
KABIKINASE - PWS 250000 UNIT/VIAL 250000 UNIT contains STREPTOKINASE : 250000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02126125, held by PHARMACIA & UPJOHN INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS ; INTRACORONARY administration. Health Canada currently lists it as cancelled post market, status dated 12-Aug-1999. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02126125 |
|---|---|
| Brand name | KABIKINASE - PWS 250000 UNIT/VIAL |
| Generic / active ingredient | STREPTOKINASE : 250000 UNIT |
| Manufacturer | PHARMACIA & UPJOHN INC |
| Strength | 250000 UNIT |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS ; INTRACORONARY |
| Schedule | Schedule D |
| ATC code | B01AD01 STREPTOKINASE |
| AHFS class | 20:12.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 12-Aug-1999 |
| Original market date | 1995-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02126125 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2126125 |
| Brand name | KABIKINASE - PWS 250000 UNIT/VIAL |
| Active ingredient / INN | STREPTOKINASE : 250000 UNIT |
| ATC code | B01AD01 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01 |
| AHFS class | 20:12.20 |
| Health Canada schedule | Schedule D |
| Biosimilar biologic | No |
| Market authorization holder | PHARMACIA & UPJOHN INC |
Which pack is which?
| Strength on the label | 250000 UNIT |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS ; INTRACORONARY |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code B01AD01 STREPTOKINASE. 0 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| KABIKINASE - PWS 1500000UNITS/VIAL | 1500000 UNIT | POWDER FOR SOLUTION | PHARMACIA & UPJOHN INC | CANCELLED POST MARKET | DIN 02126141 |
| KABIKINASE - PWS 750000UNITS/VIAL | 750000 UNIT | POWDER FOR SOLUTION | PHARMACIA & UPJOHN INC | CANCELLED POST MARKET | DIN 02126133 |
| STREPTASE | 1500000 UNIT | POWDER FOR SOLUTION | CSL BEHRING CANADA INC | CANCELLED POST MARKET | DIN 02019019 |
| STREPTASE | 250000 UNIT | POWDER FOR SOLUTION | CSL BEHRING CANADA INC | CANCELLED POST MARKET | DIN 02018993 |
| STREPTASE | 750000 UNIT | POWDER FOR SOLUTION | CSL BEHRING CANADA INC | CANCELLED POST MARKET | DIN 02019000 |
| STREPTASE INJ 1500000 UNIT/VIAL | 1500000 UNIT | POWDER FOR SOLUTION | HOECHST CANADA INC. | CANCELLED POST MARKET | DIN 00881686 |
| STREPTASE INJ 250000UNIT/VIAL | 250000 UNIT | POWDER FOR SOLUTION | HOECHST CANADA INC. | CANCELLED POST MARKET | DIN 00527157 |
| STREPTASE INJ 750000UNIT/VIAL | 750000 UNIT | POWDER FOR SOLUTION | HOECHST CANADA INC. | CANCELLED POST MARKET | DIN 00527149 |
How much does STREPTOKINASE cost around the world?
STREPTOKINASE is listed on 4 national price registers Nexara tracks, across 11 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Saudi Arabia | public | 4 | 4 | 01 Sep 2026 |
| South Africa | single exit price | 3 | 3 | 01 Sep 2026 |
| United Kingdom | hospital | 2 | 2 | 31 Aug 2026 |
| Morocco | PPV (public price) | 2 | 2 | 05 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.